168 related articles for article (PubMed ID: 33808404)
41. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.
Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T
BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970
[TBL] [Abstract][Full Text] [Related]
42. Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE(∗)3Leiden mice.
Morrison MC; Liang W; Mulder P; Verschuren L; Pieterman E; Toet K; Heeringa P; Wielinga PY; Kooistra T; Kleemann R
J Hepatol; 2015 May; 62(5):1180-6. PubMed ID: 25514555
[TBL] [Abstract][Full Text] [Related]
43. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
44. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
45. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy.
Zhang X; Han J; Man K; Li X; Du J; Chu ES; Go MY; Sung JJ; Yu J
J Hepatol; 2016 Jan; 64(1):160-70. PubMed ID: 26394162
[TBL] [Abstract][Full Text] [Related]
46. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.
Hansen HH; Jelsing J; Hansen CF; Hansen G; Vrang N; Mark M; Klein T; Mayoux E
J Pharmacol Exp Ther; 2014 Sep; 350(3):657-64. PubMed ID: 24993361
[TBL] [Abstract][Full Text] [Related]
47. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis.
Schierwagen R; Maybüchen L; Zimmer S; Hittatiya K; Bäck C; Klein S; Uschner FE; Reul W; Boor P; Nickenig G; Strassburg CP; Trautwein C; Plat J; Lütjohann D; Sauerbruch T; Tacke F; Trebicka J
Sci Rep; 2015 Aug; 5():12931. PubMed ID: 26263022
[TBL] [Abstract][Full Text] [Related]
48. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
49. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
[TBL] [Abstract][Full Text] [Related]
50. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
51. Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis.
Takai A; Kikuchi K; Ichimura M; Tsuneyama K; Moritoki Y; Matsumoto K; Tsunashima H; Onda T; Kuniyoshi N; Nariyama T; Ohyatsu S; Kubota J; Nagumo K; Sato S; Hara M; Miyakawa H
BMC Gastroenterol; 2020 Feb; 20(1):46. PubMed ID: 32103741
[TBL] [Abstract][Full Text] [Related]
52. Pitavastatin ameliorated the progression of steatohepatitis in ovariectomized mice fed a high fat and high cholesterol diet.
Kamada Y; Kiso S; Yoshida Y; Chatani N; Kizu T; Hamano M; Egawa M; Takemura T; Ezaki H; Furuta K; Hayashi N; Takehara T
Hepatol Res; 2013 Apr; 43(4):401-12. PubMed ID: 22971151
[TBL] [Abstract][Full Text] [Related]
53. Cellular cholesterol accumulation modulates high fat high sucrose (HFHS) diet-induced ER stress and hepatic inflammasome activation in the development of non-alcoholic steatohepatitis.
Bashiri A; Nesan D; Tavallaee G; Sue-Chue-Lam I; Chien K; Maguire GF; Naples M; Zhang J; Magomedova L; Adeli K; Cummins CL; Ng DS
Biochim Biophys Acta; 2016 Jul; 1861(7):594-605. PubMed ID: 27090939
[TBL] [Abstract][Full Text] [Related]
54. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
[TBL] [Abstract][Full Text] [Related]
55. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Pizarro M; Solís N; Quintero P; Barrera F; Cabrera D; Rojas-de Santiago P; Arab JP; Padilla O; Roa JC; Moshage H; Wree A; Inzaugarat E; Feldstein AE; Fardella CE; Baudrand R; Riquelme A; Arrese M
Liver Int; 2015 Sep; 35(9):2129-38. PubMed ID: 25646700
[TBL] [Abstract][Full Text] [Related]
56. Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor γ.
Zhong X; Liu H
J Gastroenterol Hepatol; 2018 Feb; 33(2):524-532. PubMed ID: 28670854
[TBL] [Abstract][Full Text] [Related]
57. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
Pennig J; Scherrer P; Gissler MC; Anto-Michel N; Hoppe N; Füner L; Härdtner C; Stachon P; Wolf D; Hilgendorf I; Mullick A; Bode C; Zirlik A; Goldberg IJ; Willecke F
Sci Rep; 2019 Nov; 9(1):17937. PubMed ID: 31784656
[TBL] [Abstract][Full Text] [Related]
58. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
[TBL] [Abstract][Full Text] [Related]
59. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
[TBL] [Abstract][Full Text] [Related]
60. CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis.
Tomita K; Freeman BL; Bronk SF; LeBrasseur NK; White TA; Hirsova P; Ibrahim SH
Sci Rep; 2016 Jun; 6():28786. PubMed ID: 27349927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
